WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
Bristol-Myers Squibb and Ambrx Announce Collaboration
22 September 2011
Bristol-Myers Squibb and Ono Enter into Strategic Agreement
21 September 2011
Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals
09 September 2011
Bristol-Myers Squibb Delivers Excellent Second Quarter
05 August 2011
Bristol-Myers Squibb to Acquire Amira Pharmaceuticals
22 July 2011
FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin
21 July 2011
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement
07 July 2011
Bristol-Myers Squibb to Expand Access to Reyataz® in sub-Saharan Africa and India
29 June 2011
Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants
27 June 2011
Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement
03 June 2011
Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY™ (ipilimumab) Approval
29 April 2011
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint
22 March 2011
Bristol-Myers Squibb Delivers Solid Fourth Quarter Results
27 January 2011
Pediatric Exclusivity For PLAVIX®
25 January 2011
People to Actively Manage Their Type 2 Diabetes
11 January 2011
KOMBIGLYZE™ XR Now Available in U.S. Pharmacies
09 January 2011
Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement
21 December 2010
Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma
07 December 2010
Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration
01 December 2010
APPRAISE-2 Study with Investigational Compound Apixaban Discontinued
21 November 2010
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
GSK completes acquisition of Sierra Oncology
Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
Research & Development
Researchers discover new leukemia-killing compounds
Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
Biomarkers found that could be drug targets against a deadly form of brain cancer
COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
Novel drug combo activates natural killer cell immunity to destroy cancer cells
Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
A new technology offers treatment for HIV infection through a single injection
Conferences & Events
New approach to treatment of deadly kidney cancer
SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
SMi's 22nd Annual Pain Therapeutics Conference
SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
SMi's 3rd Annual AI in Drug Discovery Conference
Regulatory Affairs
FDA approves first systemic treatment for alopecia areata
FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
FDA limits use of Janssen COVID-19 vaccine to certain individuals
EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
FDA approves first generic of Symbicort to treat asthma and COPD
You are here:
Home
Bristol-Myers Squibb
Bristol-Myers Squibb reports first quarter financial results